angiotensinogen News

Latest Articles

• Phase 2 Trial of Investigational Hypertension Injection Tonlamarsen Reveals Persistent Protein Suppression but Conflicting Blood Pressure Data

  Published: Mar 30, 2026

  Section: Science & Tech

  Results from the Kardinal trial presented at ACC.26 show that the monthly injectable drug tonlamarsen successfully reduces angiotensinogen levels by over 67%. However, the study fo...